The International Federation of Psoriasis Associations (IFPA) is a non-profit organization uniting national and regional psoriasis associations from around the world.
Psoriasis and psoriatic arthritis affect more than 125 million people across the world. This is a serious global health challenge, with a range of unmet needs. People with psoriasis or psoriatic arthritis may struggle to get a correct diagnosis or adequate treatment, have limited access to care or face persistent stigma and discrimination. Since our founding in 1971, we have worked to resolve these challenges facing the international psoriasis community.
As the key global psoriasis advocacy organization, IFPA campaigns on behalf of all people with psoriasis and psoriatic arthritis. Most psoriasis associations across the world are IFPA members. Our goals are to empower our members, improve living conditions for patients, raise awareness of psoriasis and psoriatic arthritis and cooperate with fellow stakeholders.
Read on to find out what makes IFPA the key global psoriasis advocacy organization.
IFPA empowers its members
We provide expertise and support to our members, facilitating their national and regional work. Through IFPA, members can exchange ideas and access the latest global psoriasis research. We also encourage the establishment of new psoriasis associations where none existed previously.
IFPA raises awareness
People with psoriasis face stigma, prejudice and discrimination on an almost daily basis. We tackle these barriers by providing accurate psoriasis information [link to Resources] to educate patients, their friends and family, healthcare providers, policy-makers and the public.
IFPA improves living conditions for patients
We call for access to early, correct diagnosis for all people with psoriasis and psoriatic arthritis. To prevent and control other psoriasis-related NCDs, we recommend early scanning of all patients. We believe affordable, high-quality, essential treatment should be easily accessible for all people with psoriasis or psoriatic arthritis.
IFPA puts psoriasis on the global agenda
We have an established track record of advocating on behalf of people with psoriasis and psoriatic arthritis. Both the WHO Resolution on Psoriasis in 2014 and the publication of the WHO Global Report on Psoriasis early 2016 are successes we helped bring about.
IFPA mobilizes psoriasis stakeholders
As a large global federation, we have the power to mobilize psoriasis stakeholders from a wide range of countries and sectors. We bring together people with psoriasis, healthcare professionals, leading experts and industry partners through events like the World Psoriasis & Psoriatic Arthritis Conference and the annual World Psoriasis Day.
IFPA collaborates for change
Meeting the unmet needs of people with psoriasis is a complex challenge. That’s why collaborate with various civil society networks and representatives from medical societies, academia and the private sector. Our joint expertise is a catalyst for change.
Vision, Mission, Goals
Achieve a world without suffering from psoriasis.
Be the global psoriasis advocacy association, with a focus on empowering our members, improving living conditions for psoriasis patients, raising awareness and cooperating with fellow stakeholders.
- Empower national psoriasis organizations by uniting them, strengthening their work and acting as their global voice.
- Improve patients’ living conditions by advocating for correct diagnosis, universal access to treatment and less discrimination and stigmatization.
- Raise psoriasis awareness through education, information and highlighting research results.
- Cooperate with relevant psoriasis stakeholders, including medical and pharmaceutical actors.
IFPA’s funding comes primarily from sponsorship by corporate partners, membership fees and projects like the IFPA World Conference.
We believe in being transparent and open about our funding. That is why we make our latest Financial Reports publicly available.
Transparency is also particularly important when it comes to our relationship with the pharmaceutical industry. We adhere to a strict Code of Practice when we engage with our corporate partners.